Navigation Links
JDRF Encouraged by Medicare Decision to Take First Step Toward Coverage of Continuous Glucose Monitors for People with Type 1 Diabetes
Date:1/13/2017

NEW YORK, Jan. 12, 2017 /PRNewswire-USNewswire/ -- JDRF, the leading global organization funding type 1 diabetes (T1D) research, is pleased to announce that after more than a decade of advocacy efforts, the Centers for Medicare & Medicaid Services (CMS) has recognized continuous glucose monitoring (CGM) devices approved by the FDA for use in making diabetes treatment decisions as durable medical equipment, a significant step toward making them eligible for coverage under Medicare. JDRF has been the leading advocate for widespread adoption of CGM technologies to manage T1D and for public and private payer coverage of these devices.

"JDRF is encouraged by this decision, which will bring us one step closer to Medicare coverage for continuous glucose monitors," said Aaron J. Kowalski, PhD, JDRF's Chief Mission Officer. "We want to thank the tireless JDRF advocates and Congressional champions who have made this progress possible." 

Continuous glucose monitors are small, wearable devices that monitor glucose levels every few minutes, day and night, which helps people with T1D to manage insulin dosing and to see whether their levels are trending high or low before they become dangerous. CGM devices are approved by the U.S. Food and Drug Administration (FDA) and prescribed by physicians, and their use is recommended by national diabetes clinical guidelines and covered by nearly all private health plans. Extensive clinical evidence shows that CGM use significantly improves diabetes management, enabling users to avoid potentially deadly low blood-sugar crises (hypoglycemia) and the devastating long-term complications associated with chronic high blood-sugar (hyperglycemia). Seniors with T1D in particular are at elevated risk for hypoglycemia, leading not only to bad health outcomes, but increased use of costly emergency room visits and hospitalizations.

Although the significant benefits of CGM use have been known since 2008, CMS had previously refused to consider covering the devices under Medicare, saying they did not meet the statutory definitions of durable medical equipment or any other category the agency could cover. People with T1D who rely on such coverage—even those who had been successfully managing their disease with the devices when they were covered by private insurance—were forced to pay out-of-pocket for CGM or go without.

Today's CMS decision is a welcome advancement, laying a pathway toward the extension of coverage for the devices that will bring the nation's largest insurer in line with the vast majority of the country's private payers. Since Medicare has determined CGM devices are durable medical equipment, the program can now cover them on a case-by-case basis. Medicare beneficiaries should work with their health care professional and CGM provider to obtain coverage.

JDRF wants to thank everyone who made today's decision possible, especially the Centers for Medicare & Medicaid Services, Diabetes Caucus co-chairs Senators Susan Collins (R-ME), Senator Jeanne Shaheen (D-NH), Representative Tom Reed (R-NY), and Representative Diana DeGette (D-CO), our congressional supporters, our allies, and the thousands of  JDRF advocates who made their voices heard in Washington, D.C. We look forward to working with the incoming Congress and administration to ensure broad and affordable access to exciting new T1D therapies like the artificial pancreas systems and to advance the interests of the T1D community at every level.

JDRF has spearheaded the drive to obtain Medicare coverage for CGMs, marshalling research, expert testimony, allied organizations and JDRF advocates from across the nation. JDRF met numerous times with officials at CMS and elsewhere in the executive branch to urge them to provide access to this life-changing technology, using the agency's existing authority. At the same time, JDRF engaged Congress, persuading 50 Senators and 275 Representatives to support legislation to require Medicare to provide CGM coverage.

JDRF is heartened by today's decision and will continue to work with officials at the Centers for Medicare & Medicaid Services to ensure robust coverage of CGMs for people with T1D on Medicare.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jdrf-encouraged-by-medicare-decision-to-take-first-step-toward-coverage-of-continuous-glucose-monitors-for-people-with-type-1-diabetes-300390684.html


'/>"/>
SOURCE JDRF
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. AngioDynamics, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
2. Conatus Pharmaceuticals Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
3. Salix Pharmaceuticals, Ltd. Stockholders Encouraged to Contact Securities Law Firm about Takeover
4. Cornerstone Therapeutics Inc. Stockholders Seeking More Money Regarding the Proposed Buyout by Chiesi Farmaceutici S.P.A. Encouraged to Contact Lawyers at Deans & Lyons
5. Parallax Achieves Major Milestone With License to Serve Medicare Part B Patients Through its RoxSan Subsidiary, Across 42 States.
6. Navitus Medicare EGWP Program Receives 5-Star CMS Rating
7. If You Have Questions about Medicare Part D, Let freds Pharmacy Help
8. NCPA: Bipartisan Senate and House Letters Urge Medicare to Finalize Transparency Proposal
9. Medicares Competitive Bidding Program Puts Beneficiaries Lives at Risk
10. Community Oncology Alliance Letter on Medicare Part B Drug Payment Model
11. Independent LTC Pharmacy Advocacy Group Urges Stronger Effort on PDP Transparency in Response to CMS Draft 2017 Medicare Part D Call Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 7D Surgical, developer of ... has purchased the 7D Surgical System to support its strategic ... Washington D.C. and Virginia.  7D Surgical has entered ... many of the premier medical facilities within those markets. ... ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that ... healthcare employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... today announced that it has become the Official Technology Partner of North Country ... AES (Advanced Event Systems) volleyball software, along with providing sport management software ...
(Date:8/21/2017)... ... ... PIXACORE , an independent full-service agency with a decade of experience ... year by MM&M. , This is the first time PIXACORE has made the Top ... PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic transformation. ...
(Date:8/20/2017)... ... August 20, 2017 , ... A total solar eclipse will occur across the ... as the moon moves between the sun and Earth. This rare event will be magnificent ... can help keep you safe on the road during the total eclipse of the sun. ...
Breaking Medicine News(10 mins):